Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9H777
UPID:
RNZ1_HUMAN
Alternative names:
Deleted in Ma29; ElaC homolog protein 1; Ribonuclease Z 1; tRNA 3 endonuclease 1; tRNase Z 1
Alternative UPACC:
Q9H777; Q9NS99
Background:
Zinc phosphodiesterase ELAC protein 1, also known as Deleted in Ma29, ElaC homolog protein 1, Ribonuclease Z 1, tRNA 3 endonuclease 1, and tRNase Z 1, plays a crucial role in cellular processes. It functions as a zinc phosphodiesterase with tRNA 3'-processing endonuclease activity, specifically involved in tRNA repair. This protein acts downstream of the ribosome-associated quality control (RQC) pathway, removing a 2',3'-cyclic phosphate from tRNAs after cleavage by ANKZF1, with subsequent processing by TRNT1.
Therapeutic significance:
Understanding the role of Zinc phosphodiesterase ELAC protein 1 could open doors to potential therapeutic strategies.